Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06312748 · ClinicalTrials.gov registry record · Phase 1
Novel Approaches for Improving Vascular Function in Veterans With HFpEF
A Phase 1 study of Inflammation and Heart Failure With Preserved Ejection Fraction, sponsored by VA Office of Research and Development.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 90
- Enrollment target
- 1
- Study location
NCT06312748: Recruiting Phase 1 study of Inflammation and Heart Failure With Preserved Ejection Fraction, sponsored by VA Office of Research and Development.
NCT06312748 is a Phase 1 study of Inflammation and Heart Failure With Preserved Ejection Fraction that is actively recruiting participants, run by VA Office of Research and Development. The registered enrollment target is 90 participants, below the 287-participant average among 132 other Inflammation trials with a reported enrollment target (69% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06312748, a Phase 1 study of Inflammation and Heart Failure With Preserved Ejection Fraction, is actively recruiting participants, sponsored by VA Office of Research and Development.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 90 participants
- Enrollment target
- 1
- Study location
Study Summary
This project will evaluate the impact of L-Citrulline, tetrahydrobiopterin (BH4), and atorvastatin administration on physical capacity and vascular function in Veterans with heart failure with preserved ejection fraction (HFpEF).
Primary Outcome
Peak change in brachial artery diameter (%)
Conditions Studied
Interventions
- DRUG Atorvastatin
- DRUG L-Citrulline
- DRUG Placebo for L-Citrulline
- DRUG BH4
- DRUG Placebo for BH4
Study Locations (1)
Utah
- VA Salt Lake City Health Care System, Salt Lake City, UT - Salt Lake City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2021-05-19 |
| Est. Completion | 2030-09-30 |
| Phase | Phase 1 |
What NCT06312748 shows while recruiting
NCT06312748 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 90 participants, a relatively small participant target, below the 287-participant average among 132 other Inflammation trials with a reported enrollment target (69% lower).
The record links to 2 conditions, with Inflammation appearing as the primary indexed condition, and to 5 interventions - of which Atorvastatin is the first listed.
NCT06312748 reports a single indexed study location in Utah.
Frequently Asked Questions
What is clinical trial NCT06312748 about?
NCT06312748 is a clinical study titled "Novel Approaches for Improving Vascular Function in Veterans With HFpEF". This project will evaluate the impact of L-Citrulline, tetrahydrobiopterin (BH4), and atorvastatin administration on physical capacity and vascular function in Veterans with heart failure with preserved ejection fraction (HFpEF).
What is the current status of trial NCT06312748?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 90 participants. The study started on 2021-05-19. Estimated completion is 2030-09-30.
What conditions does trial NCT06312748 study?
This clinical trial studies the following conditions: Inflammation, Heart Failure With Preserved Ejection Fraction.
What interventions are being tested in trial NCT06312748?
The interventions under investigation include: Atorvastatin (DRUG), L-Citrulline (DRUG), Placebo for L-Citrulline (DRUG), BH4 (DRUG), Placebo for BH4 (DRUG).
Who is sponsoring clinical trial NCT06312748?
This trial is sponsored by VA Office of Research and Development, which has 1,668 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06312748 being conducted?
This trial has 1 study location across Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Inflammation
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06312748's enrollment target sits among peer trials
90 50th of 132 higher than 83 of 132 other Inflammation trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Inflammation trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Safety, Tolerability, and Distribution of Laquinimod Eye Drops : The LION Study
RECRUITING · Phase 1
-
Salt-Sensitivity and Immunity Cell Activation
ACTIVE NOT RECRUITING · Phase 1
-
Effects of Etravirine on Endothelial Function in HIV-uninfected Adults: A Pilot Study
COMPLETED · Phase 1
-
Flaxseed Modulates Inflammation and Oxidative Stress in CF
COMPLETED · Phase 1
-
Effect of Statin Therapy on C-reactive Protein Levels in Patients With Chronic Obstructive Lung Disease (COPD)
COMPLETED · Phase 1
-
Ketone Ester And Salt (KEAS) in Older Adults
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02521311 · 90 participants · Phase 2
Assessment of Clemastine Fumarate as a Remyelinating Agent in Acute Optic Neuritis (ReCOVER)
- NCT02939573 · 90 participants · Phase 2
A Randomized Multicenter Study for Isolated Skin Vasculitis
- NCT03128879 · 90 participants · Phase 2
Venetoclax With Ibrutinib or Acalabrutinib in Pts. With High-risk CLL
- NCT03184038 · 90 participants · NA
Neurocognition in Patients With Multiple Brain Metastases Treated With Radiosurgery
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI